The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Outcomes of haplo-TBF versus MUD-FB in AML
Ali Bazarbachi, MD, American University of Beirut Medical Center, Beirut, Lebanon, talks on outcomes for patients with acute myeloid leukemia (AML) who receive haploidentical transplant with thiotepa-busulfan-fludarabine (haplo-TBF) conditioning, compared to those who receive transplant from a matched unrelated donor with fludarabine-busulfan conditioning (MUD-FB). Data from 708 AML patients who received haplo-TBF was compared to data from 2083 patients who received MUD-FB in a retrospective analysis. The analysis reported that haplo-TBF in patients with AML in first complete remission (CR1) significantly increased non-relapse mortality, but did not affect the incidence of relapse, leukemia-free survival (LFS), overall survival (OS) or relapse-free survival (RFS). For patients with AML in second complete remission (CR2), haplo-TBF significantly increased non-relapse mortality and decreased the relapse incidence, but did not influence LFS, OS or RFS. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
